
A high-quality mega-cap income stock trading at a premium valuation. Frameworks sharply disagree on it.
Mkt Cap
$338.90B
P/E
—
PEG
4.11
P/B
6.31
Dividend
2.97%
ROE
31.1%
About the business
The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care segments. The company offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; antiperspirants, deodorants, and personal cleansing products under the Native, Old Spice, Safeguard, and Secret brands; and facial moisturizers, cleaners, and treatments under the Olay and SK-II brands. It also provides blades, razors, shave products, appliances, and other grooming products under the Braun, Gillette, and Venus brands. In addition, the company offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brands; and gastrointestinal, pain relief, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. Further, it provides fabric enhancers, and laundry additives and detergents under the Ariel, Downy, Gain, and Tide brands; and air and dish care, P&G professional, and surface care under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. Additionally, the company offers baby wipes, and taped diapers and pants under the Luvs and Pampers brands; adult incontinence and menstrual care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. It sells its products through mass merchandisers, social and e-commerce channels, grocery and specialty beauty stores, membership club stores, drug and department stores, distributors, wholesalers, airport duty-free and high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.
Who would buy PG?
Consensus 27/100 · Polarized · Investors strongly disagree — this is where Prism is most useful.
Endorses
· 3 frameworksROE > 20% 31.1% clears "> 20.0%".
ROE > 20% 31.1% clears "> 20.0%".
Dividend Yield > 2% 3.0% clears "> 2.0%".
7 insiders sold $55.5M on a discretionary basis. Discretionary selling carries more signal than planned disposals, but insiders sell for many non-thesis reasons (taxes, diversification, life events) — do not over-read it. Over the 6M window, insiders are net sellers by 11,977 shares.
In Prism's context
Insider selling is worth flagging but insiders sell for many non-thesis reasons. Read alongside the framework verdict (Fails criteria).
| Insider | Role | Type | Date | Shares | Avg price | Value | Own |
|---|---|---|---|---|---|---|---|
| PORTMAN ROBERT JONES | Director | Award / grant | Mar 10, 2026 | 193 | $0.00 | $0 | Direct |
| PORTMAN ROBERT JONES | Director | Award / grant | Mar 10, 2026 | 49 | $0.00 | $0 | Direct |
| MCEVOY ASHLEY | Director | Award / grant | Mar 10, 2026 | 161 | $0.00 | $0 | Direct |
| MCCARTHY CHRISTINE M. | Director | Award / grant | Mar 10, 2026 | 209 | $0.00 | $0 | Direct |
| JIMENEZ JOSEPH JR | Director | Award / grant | Mar 10, 2026 | 273 | $0.00 | $0 | Direct |
| ARNOLD CRAIG | Director | Award / grant | Mar 10, 2026 | 161 | $0.00 | $0 | Direct |
| KEMPCZINSKI CHRISTOPHER J | Director | Award / grant | Mar 10, 2026 | 201 | $0.00 | $0 | Direct |
| FRANCISCO MA. FATIMA | Officer | Open-market sell | Feb 27, 2026 | 5,549 | $165.29 | $917K | Direct |
| WHALEY SUSAN STREET | Officer | Open-market sell | Feb 19, 2026 | 1,809 | $159.45 | $288K | Direct |
| AGUILAR MOSES VICTOR JAVIER | Officer | Open-market sell | Feb 13, 2026 | 15,169 | $162.28 | $2.46M | Direct |
| AGUILAR MOSES VICTOR JAVIER | Officer | Option exercise | Feb 13, 2026 | 15,169 | $91.07 | $1.38M | Direct |
| COOMBE GARY A | Officer | Open-market sell | Feb 12, 2026 | 36,093 | $162.33 | $5.86M | Direct |
| COOMBE GARY A | Officer | Option exercise | Feb 12, 2026 | 36,093 | $78.52 | $2.83M | Direct |
| MOELLER JON R | Officer and Director | Open-market sell | Feb 12, 2026 | 173,268 | $162.29 | $28.12M | Direct |
| MOELLER JON R | Officer and Director | Option exercise | Feb 12, 2026 | 173,268 | $113.23 | $19.62M | Direct |
| PURUSHOTHAMAN BALAJI | Officer | Open-market sell | Feb 11, 2026 | 12,827 | $160.31 | $2.06M | Direct |
| PURUSHOTHAMAN BALAJI | Officer | Option exercise | Feb 11, 2026 | 12,827 | $91.07 | $1.17M | Direct |
| FRANCISCO MA. FATIMA | Officer | Open-market sell | Feb 4, 2026 | 8,000 | $158.00 | $1.26M | Direct |
| PRITCHARD MARC S | Officer | Open-market sell | Jan 23, 2026 | 95,903 | $151.15 | $14.50M | Direct |
| PRITCHARD MARC S | Officer | Option exercise | Jan 23, 2026 | 95,903 | $80.29 | $7.70M | Direct |
| PORTMAN ROBERT JONES | Director | Award / grant | Dec 9, 2025 | 54 | $0.00 | $0 | Direct |
| MCEVOY ASHLEY | Director | Award / grant | Dec 9, 2025 | 215 | $0.00 | $0 | Direct |
| MCCARTHY CHRISTINE M. | Director | Award / grant | Dec 9, 2025 | 269 | $0.00 | $0 | Direct |
| JIMENEZ JOSEPH JR | Director | Award / grant | Dec 9, 2025 | 341 | $0.00 | $0 | Direct |
| ARNOLD CRAIG | Director | Award / grant | Dec 9, 2025 | 215 | $0.00 | $0 | Direct |
| KEMPCZINSKI CHRISTOPHER J | Director | Award / grant | Dec 9, 2025 | 260 | $0.00 | $0 | Direct |
| RAMAN SUNDAR G. | Officer | Option exercise | Dec 3, 2025 | 59 | $145.41 | $9K | Direct |
| DAVIS JENNIFER L | Officer | Option exercise | Dec 3, 2025 | 60 | $145.38 | $9K | Direct |
| WHALEY SUSAN STREET | Officer | Option exercise | Dec 3, 2025 | 54 | $145.39 | $8K | Direct |
| PURUSHOTHAMAN BALAJI | Officer | Option exercise | Dec 3, 2025 | 38 | $145.37 | $6K | Direct |
| BHARUCHA FREDDY P | Officer | Option exercise | Dec 3, 2025 | 45 | $145.38 | $7K | Direct |
| JEJURIKAR SHAILESH | Chief Operating Officer | Option exercise | Dec 3, 2025 | 51 | $145.39 | $7K | Direct |
| FRANCISCO MA. FATIMA | Officer | Option exercise | Dec 3, 2025 | 73 | $145.40 | $11K | Direct |
| AGUILAR MOSES VICTOR JAVIER | Officer | Option exercise | Dec 3, 2025 | 55 | $145.40 | $8K | Direct |
| SCHULTEN ANDRE | Chief Financial Officer | Option exercise | Dec 3, 2025 | 88 | $145.39 | $13K | Direct |
| PRITCHARD MARC S | Officer | Option exercise | Dec 3, 2025 | 94 | $145.39 | $14K | Direct |
| MOELLER JON R | Chief Executive Officer | Option exercise | Dec 3, 2025 | 159 | $144.48 | $23K | Direct |
Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.1% of shares outstanding.
Net 6M: -11,977 sh
Price history
Drag across the chart to select a custom period — all analysis below refocuses to that window.
What this means: Price near 52-week lows confirms what most frameworks are already flagging: the market is discounting deteriorating fundamentals.
Add The Procter & Gamble Company at a hypothetical weight and Prism recalculates your whole book:
Sharpe, Sortino, volatility, max drawdown, beta — before and after.
How much this shifts your top sector weight and overall diversification.
Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.
Portfolio analytics are part of the member experience.
Sign in to run this simulationPG: 48% estimated probability of outperforming over the next 12M window. 1 of 6 signal families negative (medium confidence). Strongest support: ROE 31%. Main risk to monitor: 23% above fair value.
Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.
Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.
P/B 6.31× · FCF yield 3.8%
23% above fair value
Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.
Operating leverage kicks in or a new product line scales — margins inflect higher, growth steps up by 200–400 bps, and the multiple re-rates as the durability becomes obvious to a wider audience.
Business continues to compound at recent rates — 23% operating margin holds, 7% top-line growth persists, capital allocation stays disciplined. Multiple stays roughly where it is.
Sector: Consumer Defensive. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.
| Metric | PG | GCC median | MENA median | Global ex-US |
|---|---|---|---|---|
| P/E (TTM) | — | 18.0× | 15.0× | 17.0× |
| P/B | 6.31× | 3.50× | 2.80× | 3.20× |
| Dividend yield | 2.97% | 3.20% | 2.80% | 2.60% |
| ROE | 31.1% |
Reported EPS $1.59 vs $1.42 expected — well outside the normal beat-and-raise band. The market typically rewards a print this size only if it is read as durable, not one-off. Trailing operating margin: 23.0%.
Confirms operating leverage — 6% trailing EPS growth + a beat of this size is the pattern that drives multi-year re-rates.
If ROE (31%) and operating margin (23%) are stable or rising, the beat is consistent with compounding rather than one-off.
A blow-out can pull future quarters forward — value investors will look for sustained margin, not a single-quarter spike.
Next earnings
Wed, Jul 29 · consensus EPS $1.42 · last actual $1.59
Men's Skincare Products Market Report 2026: L'Oreal, P&G, Unilever, and Beiersdorf Dominate Through Strong Brand Equity, Extensive Distribution Channels, and Continuous Innovations - Forecast to 2031
GlobeNewswire · just now
Is Procter & Gamble's Baby Care Slump Dragging Overall Growth?
Zacks · just now
These Are the 10 Largest Consumer Staples Stocks in May -- How to Pick the Top Investments
P/E Ratio (TTM)
N/A
PEG Ratio
4.11
P/B Ratio
6.31
EPS Growth
5.8%
Revenue Growth
7.4%
Debt / Equity
0.68
Net Cash / Share
$-10.62
Return on Equity
31.1%
Gross Margin
51.0%
Operating Margin
23.0%
FCF / Share
$5.47
Current Ratio
0.73
Rejects
· 3 frameworksPEG < 1 (growth at a discount) is 4.11× — fails "< 1.00×".
P/B < 1.0 (below book) is 6.31× — fails "< 1.00×".
FCF Yield > 7% is 3.8% — fails "> 7.0%".
Trades meaningfully above the fair-value range — limited margin of safety.
Returns and margins are healthy and consistent.
Leverage is high relative to coverage — balance-sheet risk on the table.
Price trend is unremarkable — neither tailwind nor headwind.
Informed money is leaning the other way — net selling or thin interest.
Mixed catalyst picture.
Among 98 historical setups with similar Prism Score and signal-agreement profiles, 49% beat the benchmark over the next 12 months, with average excess return of -0.2% / yr.
ROE 31% · Op margin 23%
D/E 0.68 · CR 0.73
Net selling — 9 insiders
No tracked superinvestor holds it
2.97% yield + buyback runway
24% through 52w range
EPS 6% · Rev 7%
A growth-rate scare or a quarter of margin compression resets the multiple. The business is still fine, but the price was assuming a level of compounding that takes 12–24 months to re-prove.
| 18.0% |
| 16.0% |
| 14.0% |
Motley Fool · just now
Institutional Own.
70.4%
Insider Own.
0.1%
Dividend Yield
2.97%
Book Value / Share
$23.08